81. Congenital adrenal hyperplasia Clinical trials / Disease details
Clinical trials : 88 / Drugs : 90 - (DrugBank : 23) / Drug target genes : 12 - Drug target pathways : 68
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2021-004467-26-FR (EUCTR) | 09/12/2021 | An Open-label Extension Study to Evaluate the Long-term Safety andTolerability of Chronocort in the Treatment of Participants Aged 16 Years and Over with Congenital Adrenal Hyperplasia | A Phase 3 Open-label Extension Study to Evaluate the Long-term Safety andTolerability of Chronocort in the Treatment of Participants Aged 16 Years and Over with Congenital Adrenal Hyperplasia | Congenital Adrenal Hyperplasia due to 21-hydroxylase deficiency;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Efmody 5 mg modified release hard capsules Product Name: Chronocort 5mg INN or Proposed INN: HYDROCORTISONE Other descriptive name: HYDROCORTISONE MICRONIZED Trade Name: Efmody 10 mg modified release hard capsules Product Name: Chronocort 10mg INN or Proposed INN: hydrocortisone Other descriptive name: HYDROCORTISONE MICRONIZED | Diurnal Limited | NULL | NA | Female: yes Male: yes | 181 | Phase 3 | United States;France;Japan |